About 38% to 73% of patients diagnosed with BE with HGD and who went on to have an esophagectomy already had esophageal ACA. The low 5-year survival rate of invasive esophageal ACA places pressure on the physician to find a way to prevent or to remove the cancer. Endoscopic ablative therapies have been developed, but these new technologies are to be considered as a secondary option. Although there are many recent improvements in surveillance strategies and endoscopic ablative therapies, series are small and follow-up is short. These modalities do show promise and may be a good option in the future for patients who are poor surgical candidates. At the present time, the standard of care for BE with HGD in good surgical candidates is still esophagectomy.
ASJC Scopus subject areas